Hemant Surgical Industries Ltd

Hemant Surgical Industries Ltd has announced that its 37th Annual General Meeting (AGM) for the financial year 2025-26 will be held on September 29, 2026. The meeting will be conducted virtually through Video Conferencing/Other Audio Visual Means (VC/OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the re-appointment of a director retiring by rotation, and the ratification of remuneration for the Cost Auditors, M/s. K Sorathiya & Co, for the financial years 2025-26 and 2026-27.

Hemant Surgical Industries Ltd has released its Integrated Annual Report for FY 2025-2026, along with the notice for its 37th Annual General Meeting (AGM). The AGM is scheduled for Tuesday, September 29, 2026, at 12:30 PM IST and will be conducted via Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The report and notice have been sent electronically to shareholders and are also available on the company's website. The annual report includes company overview, management report, financial statements (standalone and consolidated), and details on the board of directors and key managerial personnel.

Hemant Surgical Industries Ltd has issued letters to shareholders whose email addresses are not registered, providing a weblink to access the AGM Notice and Integrated Annual Report. This action complies with SEBI regulations. The 37th Annual General Meeting is scheduled for September 29, 2026, via Video Conferencing. The company is ensuring all shareholders can access crucial AGM documents despite missing email information.

Hemant Surgical Industries Ltd announced that its Board of Directors has approved the Directors' Report and Management Discussion and Analysis Report for the financial year ended March 31, 2026. The company will hold its 37th Annual General Meeting (AGM) on September 29, 2026, at 12:30 P.M. (IST) via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The board meeting where these decisions were made was held on August 29, 2026.

Hemant Surgical Industries Ltd has made minor modifications to a previously filed disclosure dated March 31, 2026. The updated disclosure, submitted at the request of Sonomed Escalon, USA, clarifies the Semi Knocked Down (SKD) manufacturing agreement for ophthalmic ultrasound devices in India. The agreement focuses on distributing two designated A-scan and pachymetry models exclusively within the Indian market. Sonomed Escalon will supply components in SKD form at a preferential 'Transfer Price'. The filing confirms no shareholding in Sonomed Escalon, no special rights for Sonomed, and that the parties are not related, although the promoter was a prior authorized distributor. The transaction is not considered a related party transaction and is conducted at arm's length.

Hemant Surgical Industries Limited has acquired a 66.66% majority stake in Lifesenz Cancer Research Labs Private Limited for ₹19.98 Crores, making Lifesenz a subsidiary. This strategic move expands Hemant Surgical's healthcare portfolio into the high-growth precision oncology segment. Lifesenz specializes in personalized cancer treatment solutions through advanced ex-vivo chemo-sensitivity analysis. The acquisition aligns with Hemant Surgical's long-term strategy to participate in emerging areas of advanced diagnostics and precision medicine, leveraging Lifesenz's scientific capabilities and existing collaborations. While Lifesenz is currently in a growth phase, the company anticipates future revenue growth and long-term shareholder value creation through scaling operations, strengthening collaborations, and increasing commercialization opportunities.

Hemant Surgical Industries Ltd has completed the acquisition of Lifesenz Cancer Labs Private Limited, effective June 01, 2026. As a result of this acquisition, Lifesenz Cancer Labs has become a subsidiary of Hemant Surgical Industries.

Hemant Surgical Industries Ltd has entered into a Share Purchase Agreement (SPA) on May 27, 2026, to acquire 66.66% equity shareholding of Lifesenz Cancer Research Labs Private Limited, Mumbai. The acquisition, subject to certain conditions, will make Lifesenz Cancer Research Labs a subsidiary of Hemant Surgical. The cost of acquisition is ₹19,99,80,000 in cash. This acquisition is aimed at expanding Hemant Surgical's presence in the healthcare and cancer diagnostic support segment. The target entity's turnover for FY 24-25 was ₹56.75 Lakhs, with a net loss of ₹(74.76) Lakhs and a net worth of ₹(221.84) Lakhs.

Singularity Equity Fund I acquired 6,49,600 equity shares of Hemant Surgical Industries Ltd through the conversion of warrants, increasing its total holding to 8,99,200 shares, representing 6.90% of the post-acquisition equity share capital. The acquisition occurred on May 15, 2026, via preferential allotment. Post-acquisition, the equity share capital of Hemant Surgical Industries Ltd stands at ₹14,53,76,000.

Singularity Large Value Fund III acquired a 4.98% stake in Hemant Surgical Industries Ltd through the conversion of convertible warrants into 6,49,600 equity shares. This acquisition, dated May 15, 2026, increased Singularity Large Value Fund III's total holding to 6.90% post-acquisition. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.